Programs & Expertise
LinusBio Precision Exposome Medicine Program Follows The Evolving Precision Medicine Paradigm
LinusBio is developing and commercializing hair strand tests for complex health conditions.
A substantial need exists for new biomarkers, especially for CNS conditions and GI disorders caused by the interplay of genetics and the environment. Extensive research in these areas has yet to result in genetic tests to guide diagnosis and treatment choices. Without biological tests, doctors continue to rely on questionnaires and specialists’ observations of symptoms for their clinical decision-making.
Our goal is to bring precision exposome medicine to patients with autism, ADHD, schizophrenia, ALS, irritable bowel syndrome, and other complex conditions lacking biomarkers with evidence of clinical utility.
Imagine if a lab test:
We are working to make this vision a reality. Temporal exposomic sequencing has the potential to transform how complex disorders are diagnosed and treated. Our tests might identify conditions before symptoms appear, aid in diagnosing and monitoring the progression of health conditions, serve as objective molecular endpoints in clinical trials, characterize the response to treatment, and more.
|Disorder Type||Disorder||Patent & PCT Submitted||Clinical & Epid. Studies||Pathway Characterization||Current Status|
|CNS||1001 – Early Autism Detection||FDA Breakthrough Designation granted|
|CNS||1002 – Attention Deficit Hyperactive Disorder||Enrollment ongoing|
|CNS||1003 — Psychosis & schizophrenia||Enrollment ongoing|
|CNS||1004 – Lou Gehrig’s Disease||FDA submission Q2 2022|
|Gut||IBS, Eosinophilic Esophagitis, Microbiome||Enrollment ongoing|
|Cancer||Pediatric Cancer||Enrollment ongoing|
|Data Science||Global biodynamics dataset||Prototype complete|